Our Website Uses Cookies
We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.
For more information, please contact us or consult our Privacy Notice.
Your binder contains too many pages, the maximum is 40.
We are unable to add this page to your binder, please try again later.
This page has been added to your binder.
Gregor Frizzell is a partner in, and a vice-chair of, Covington’s Corporate Practice Group. He is resident in the firm's London office. Mr. Frizzell's practice focuses on cross-border mergers and acquisitions and he also regularly advises clients on complex and strategic collaborations. His experience includes venture capital transactions, securities and finance, joint ventures, and general corporate and commercial advice. He has particular experience in the life sciences, energy, and technology sectors.
- Represented AstraZeneca in connection with the $350,000,000 divestment of its rights to various respiratory products outside the U.S.
- Represented AstraZeneca in connection with its strategic oncology collaboration with Innate Pharma S.A., including with respect to its acquisition of a nine percent interest in Innate Pharma.
- Represented AstraZeneca in connection with its strategic joint venture with the Chinese Future Industry Investment Fund (FIIF) to discover, develop, and commercialize potential new medicines.
- Represented one of the world’s leading tire manufacturers in connection with three acquisitions of U.K. based digital technology companies.
- Represented AstraZeneca in connection with its $538,000,0000 divestment of its international rights to Seroquel.
- Represented AstraZeneca in connection with its $330,000,000 $divestment of its rights to Rhinocort Aqua outside the U.S.
- Represented AstraZeneca in connection with two separate divestments of its global anaesthetics portfolio to Aspen Pharma.
- Represented leading energy company in connection with its acquisition of interests in renewable energy assets in the Middle East.
- Represented a global consumer goods company on its acquisition of a UK-based technology company.
- Represented leading global biotechnology company in its acquisition of UK-based drug discovery company.
- Represented leading global biotechnology company on its acquisition of a European based company.
- Represented an investor in relation to the acquisition of oil and gas blocks in Africa.
- Represented Magticom, Georgia’s leading telecoms company, in connection with a $100,000,000 loan from The European Bank for Reconstruction and Development for the acquisition of a fixed-line broadband internet network.
- Represented AstraZeneca in connection with its strategic transaction with Almirall S.A.
- Represented global pharmaceutical company in connection with its entry into a drug discovery joint venture with a partner in Japan.
- Represented Allergan plc in connection with its acquisitions of 2 UK based early-stage companies.
- Represented leading global mining and industrial company with the structuring and creation of its joint ventures in Turkey, Brazil, and Morocco.
- Represented global pharmaceutical company in connection with its entry into a drug discovery joint venture with a partner in Korea.
- Represented a global medical device company on its acquisition of a smaller, German-based medical device company.
- Represented AstraZeneca in connection with the out-license of its European rights to Moventig.
- Represented AstraZeneca in connection with the acquisition of rights to Actavis' Branded Respiratory Portfolio.
- Represented AstraZeneca in connection with its $450,000,000 acquisition of Takeda’s Respiratory Business.
- Represented MedImmune Ventures in connection with its investments in ADC Therapeutics.
- Represented Consort Medical in connection with its acquisition financing facility of £160,000,000 to be used in connection with the acquisition of Aesica Holdco.
- Represented lead and other investors in numerous investments into UK tech companies, including in Blippar, Fon, Chargemaster, Yplan, ip.access, Zesty, and others.
- Represented lead investors in funding rounds of Formula E Holdings Limited.
- Represented ICICI Bank Limited and Standard Chartered Bank, as joint lead arrangers, on an aggregate of U.S. $925m in project financing supporting two Reliance Group infrastructure companies.
- Represented Cenkos Securities PLC in relation to Tanfield Group PLC’s £115m placing of ordinary shares on AIM.
- Represented telecoms borrower in relation to a $25m junior working capital facility.
- Represented Thomson Reuters on English law aspects of the sale of its Medical Education business to ABRY Partners.
- Represented SR One Limited, a venture capital fund, the lead investor in the Series C funding round for Addex Pharmaceuticals SA, a Swiss biotech company.
- Represented Vantage Point Venture Partners on its Series A investment in Solar Century Holdings Limited.
- Represented Giorgio Armani S.p.A. in relation to a cross-border acquisition and joint venture and on related licensing and franchising arrangements.
- Represented QUALCOMM Inc. on its acquisitions of two UK venture-backed 3G-related software companies.
- Represented a UK-listed private equity fund of funds on its recent share redemption.
- Represented an early stage English biotech company on its Series B venture funding round.
- Represented the majority shareholders of a UK venture-backed software company on the trade sale of the company to a U.S.-listed buyer.
- Represented the founder and director of a UK software company in connection with the Series A venture funding round of his company.
- Represented a U.S.-listed vaccines company on the spin-out of one of its medical device businesses to a venture-backed UK new company.
May 29, 2020, Covington Alert
The UK Government has released the full details of its Future Fund scheme, including the application process, together with the template convertible loan agreement. The Future Fund, the headline terms of which were announced on 20 April 2020 (see our Alert of 22 April), launched on 20 May 2020 and will initially be open until the end of September 2020. The ...
April 22, 2020, Covington Alert
On 20 April 2020, the UK Government announced the new Future Fund scheme under which the Government will offer funding to innovative UK registered companies facing financial difficulties due to the COVID-19 outbreak.
April 5, 2020, Covington Alert
With its announcements on Friday 3 April 2020, the UK government has now introduced three different schemes to facilitate access to Coronavirus finance for larger, mid-sized and smaller businesses in UK. Three separate schemes have been established to reflect the varied issues that business of different sizes have been encountering. Each scheme seeks to directly ...
April 3, 2020, Covington Alert
On 28 March, 2020, the UK Government announced that it intends to amend insolvency law to give companies breathing space and allow them to keep trading while they explore options for rescue. The changes include (a) a temporary suspension of wrongful trading by directors of UK companies for three months commencing on 1 March, 2020 and (b) the introduction of a ...
April 3, 2020, Covington Alert
At a time when many companies have been forced to close their offices and have almost all of their employees working remotely, the standard procedures for the execution of documents and addressing signing and closing matters have come under pressure. Below are some practical issues that can arise in the signing and closing of deals which are subject to English ...
January 17, 2020
WASHINGTON—Covington represented Piramal Enterprises Limited in itsdefinitive agreement to sell Decision Resources Group to Clarivate Analytics plc, in a deal valued at $950 million. The $950 million purchase price includes $900 million in cash and approximately $50 million in Clarivate ordinary shares to be issued following the one-year anniversary of ...
May 20, 2019
NEW YORK—Covington advised LifeArc, a UK-based medical research charity, on its monetization of a portion of its royalties relating to Keytruda® for $1.297 billion (approximately £1 billion). This royalty monetization is the largest single-product royalty monetization ever done by a non-profit. The transaction closed on May 10, 2019, the culmination of efforts ...
October 7, 2016
LONDON—Covington advised AstraZeneca on its agreement with Cilag GmbH International, an affiliate of Johnson & Johnson, for the divestment of the rights to Rhinocort Aqua outside the U.S. Rhinocort Aqua is a nasal spray indicated for allergic and non-allergic rhinitis (inflammation of the inside of the nose), and for the treatment of nasal polyps (swelling of ...
March 1, 2016
LONDON — Covington advised AstraZeneca on an agreement with ProStrakan Group, a subsidiary of Kyowa Hakko Kirin Co. Ltd., for the rights to Moventig (naloxegol) in the European Union (EU), Iceland, Norway, Switzerland and Liechtenstein. Moventig is the first once-daily, oral peripherally-acting mu-opioid receptor antagonist (PAMORA) approved in Europe for the ...
December 17, 2015
LONDON, 17 December, 2015 — Covington advised AstraZeneca on its acquisition of Takeda’s respiratory business. Under the terms of the agreement, AstraZeneca will make a payment of $575 million, and approximately 200 staff will transfer to AstraZeneca upon completion. The deal will include the expansion of rights to roflumilast (marketed as Daliresp in the ...
Covington Advises AstraZeneca on Acquisition of Rights to Actavis' Branded Respiratory Portfolio
February 5, 2015
LONDON, 5 February, 2014 — Covington advised AstraZeneca on its acquisition of the rights to Actavis' branded respiratory business in the US and Canada for an initial consideration of $600 million on completion and low single-digit royalties above a certain revenue threshold. Upon completion of the transaction, AstraZeneca will own the development and ...
Covington Advises Consort Medical on Aesica Holdco Acquisition and related £260 million financing
October 10, 2014
LONDON, 10 October, 2014 — Covington & Burling is advising Consort Medical plc on the acquisition of Aesica Holdco Limited and its operating subsidiaries from private equity fund Silverfleet Capital and its management shareholders for a total consideration of approximately £230 million. Covington is also advising Consort Medical plc on the £98.9 million Rights ...
Covington Advises AstraZeneca on Strategic Transaction with Almirall in Respiratory Disease
July 30, 2014
LONDON, 30 July, 2014 — Covington & Burling advised AstraZeneca on its agreement to transfer to the company the rights to Almirall’s respiratory franchise for an initial consideration of $875 million on completion, and up to $1.22 billion in development, launch, and sales-related milestones. AstraZeneca has also agreed to make various sales-related payments. ...
July 30, 2014, Legal Business
Lucinda Osborne, Gregor Frizzell, Christopher Walter and Miranda Cole are mentioned regarding their representation of AstraZeneca on its £1.2bn acquisition of Spanish healthcare group Almirall’s respiratory unit.
January 13, 2014
LONDON, 13 January, 2014 — Covington & Burling advised Isarna Therapeutics GmbH on an agreement with Santaris Pharma A/S whereby Isarna gains access to Santaris' Locked Nucleic Acid (LNA) technology to further develop its next generation oligonucleotide product candidates. Under the terms of the agreement, Isarna obtains rights to utilize Santaris Pharma's ...
Covington Advises AstraZeneca/ MedImmune on Acquisition of Spirogen and Investment in and Collaboration with ADC Therapeutics
October 18, 2013
LONDON, 18 October, 2013 — AstraZeneca announced that MedImmune, its global biologics research and development arm, has acquired Spirogen, a privately-held biotech company focused on antibody-drug conjugate technology for use in oncology. Covington & Burling advised AstraZeneca on the transaction working alongside AstraZeneca’s in-house legal team. MedImmune has ...
Covington Advises Resource America In Global Credit Deal
January 4, 2012
NEW YORK, January 4, 2012 — Covington & Burling advised Resource America, Inc. in its definitive agreement with CVC Capital Partners to create a global credit management business with over $7.5 billion in assets under management called CVC Credit Partners. As part of the transaction, Resource America plans to sell Apidos Capital management, its CLO manager, to ...
March 15, 2011
NEW YORK, March 15, 2011 — Covington & Burling LLP advised ClaimTrust, Inc. in the company’s recent sale to Craneware PLC (AIM: CRW.L). Craneware PLC is the market leader in automated revenue integrity solutions for the U.S. healthcare market. ClaimTrust, Inc. is a software-as-a-service revenue cycle technology provider to hospitals in the United States. The ...
Covington Promotes 12 Lawyers to the Partnership
10/1/2008
WASHINGTON, DC, October 1, 2008 — Covington & Burling LLP today announced that 12 of its lawyers have been elected to the firm’s partnership. These new partners are resident in four of the firm’s offices and practice in the litigation, corporate/tax, and regulatory fields. Timothy Hester, chair of the firm’s management committee, commented: “These young and ...
November 15, 2007
NEW YORK, NY, November 15, 2007 — Hellenic Telecommunications Organization S.A., the Greek landline telephone company known as OTE that is listed on the Athens, London, and New York stock exchanges, has announced its tender offer for all issued and outstanding shares of Cosmote Mobile Telecommunications S.A., the Greek wireless carrier listed in Athens and ...
8/7/2007
LONDON, 7 August, 2007 - Covington & Burling LLP acted for Cenkos Securities plc in its role as nominated adviser and joint broker to Tanfield Group Plc in Tanfield’s £115 million placing of ordinary shares. Tanfield, the AIM-listed manufacturer of zero emission electric vehicles and aerial work platforms, will use part of the proceeds from the placing to fund ...
May 8, 2007
LONDON, 8 May, 2007 — Covington & Burling LLP today announced its role in advising ICICI Bank Limited, India’s 2nd largest bank, and Standard Chartered Bank, India’s largest international bank, as joint lead arrangers for an aggregate of US$925m in project financings supporting two separate projects being undertaken separately by Reliance Ports and Terminals ...
4/16/2007
NEW YORK, NY, April 16, 2007 — The Thomson Corporation closed the sale of its Thomson Medical Education business to ABRY Partners, a Boston based private equity firm. Covington & Burling LLP advised The Thomson Corporation on the transaction. The Thomson Corporation is a leading global provider of integrated information-based solutions to business and ...
- Legal 500 UK, M&A Premium Deals (2015-2016)
- Legal 500 UK, Venture Capital (2015-2016)
- Super Lawyers - London Rising Stars, Mergers & Acquisitions (2013)
COVID-19: Legal and Business Toolkit
We are helping clients around the world navigate this evolving, complex situation.